NCT07386639Completed
Sex-Specific Machine Learning Models to Predict Distant Metastasis in Liver Cancer
Gender-Specific Prediction Models for Hepatocellular Carcinoma Metastasis: A Machine Learning-Based Retrospective Cohort Study
Source: ClinicalTrials.gov · Last updated 4 Feb 2026
Brief summary (registry, in English)
This study looked at whether male and female patients with liver cancer (hepatocellular carcinoma, HCC) have different risks of the cancer spreading to distant parts of the body (distant metastasis). Liver cancer is much more common in men than in women, and women often have better survival rates. However, it was unclear if the factors that predict this spread are the same for both sexes. To answer this question, researchers analyzed information from a large, national cancer database (SEER) from 2004 to 2022, including 19,019 patients diagnosed with liver cancer. They studied factors like age, race, tumor stage, treatment received, and where patients lived. The team used advanced computer models (machine learning) to build separate prediction tools for men and women to estimate their risk of distant metastasis at the time of diagnosis.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 19019 (actual)
- First submitted
- 23 Jan 2026
- Start date
- 1 Jan 2004
- Primary completion date
- Jan 2023
- Lead sponsor
- Tongji University
- Diseases
- Liver and biliary tract cancer
- NCT number
- NCT07386639
What you commit to
- Study type: Observational
- Participants enrolled: 19019
- From 1 Jan 2004 to the primary completion date, Jan 2023
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Missing information on race, marital status, tumor grade, or surgical status.
Other illness
- Non-first primary malignancy or presence of multiple primary tumors.
Other
- Incomplete TNM staging data.
Who the study is looking for
- Pathologically confirmed diagnosis of Hepatocellular Carcinoma (HCC).
- Diagnosis year between 2004 and 2022, inclusive.
- Case identified within the 22 registries of the Surveillance, Epidemiology, and End Results (SEER) database.
Age in the registry: 18 years to 100 years · Sex: All · Does not accept healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.